Hi tada.

I really should not have posted the "what if" stuff. It was pointless. I haven't read ahead on todays' posts and perspectives at this stage because I don't have time.

I agree with you that in fact there are many differences between the past trials and this trial. One key difference is the very tight definition of the patient population. Another is a much bigger trial and trial length. Another is the balance of Crestor and lipitor. This is just the differences that come to mind. There are more.

Also, if we look at the 3 pt MACE trial from previous combined trials while is is not a statistically reliable data set because it is miniscule in sample size the 3 pt MACE RRR is about 70% as I recall.

Now on the positive side if the financing with the Bloom Burton financing plus the 3rd Eye loan move forward I hope it will get BoM to a successful SSA and hopefully a bit further. Yes, it's not ideal but it is reality. It will cost allot of money and dilute but if apabetalone works the way I believe it will I'm not worried about cost. I want to see this trial completed with RVX as an operating business concern.

Once again, apologies for that post of mine.

Cheers

Toinv